UBS analyst Peter Grom lowered the firm’s price target on Clorox (CLX) to $115 from $119 and keeps a Neutral rating on the shares. The operating environment and market backdrop for Consumer Staples remains challenging, but fundamentals could improve in 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Clorox price target lowered to $108 from $117 at TD Cowen
- Clorox price target lowered to $94 from $110 at Goldman Sachs
- Clorox price target lowered to $108 from $117 at Wells Fargo
- GM, CLX, KMB: Maduro Capture Fails to Lift Venezuelan Seized Assets Stocks
- Clorox price target lowered to $110 from $125 at BofA